Screening for ICU-Related Peripheral Nerve Dysfunction: Evidence, Mechanisms, and Clinical Approaches

Abstract

Intensive Care Unit (ICU)-related peripheral nerve dysfunction, encompassing critical illness polyneuropathy (CIP) and critical illness myopathy (CIM), is a common and significant source of morbidity in critically ill patients. This review synthesizes current evidence on the epidemiology, pathophysiology, risk factors, clinical features, diagnostic approaches, management strategies, recent advances, and guideline recommendations related to screening for ICU-associated peripheral nerve dysfunction. Emphasis is placed on mechanism-based understanding, early detection, and translating research into improved patient outcomes.

Introduction

Peripheral nerve dysfunction acquired during ICU admission is a frequent and debilitating complication in critically ill patients, often contributing to prolonged weaning from mechanical ventilation, extended hospital stays, and persistent functional deficits. The primary entities critical illness polyneuropathy (CIP) and critical illness myopathy (CIM) can develop in up to half of patients requiring prolonged ICU care. Early identification and management are essential for optimizing recovery and reducing long-term disability. This review provides a comprehensive, evidence-based overview for clinicians.

Epidemiology / Disease Burden

ICU-acquired peripheral nerve dysfunction is reported in 25-60% of patients with sepsis, multiorgan failure, or those requiring extended mechanical ventilation. Studies, including large multicenter cohorts, demonstrate a particularly high incidence among patients with severe sepsis or acute respiratory distress syndrome (ARDS). The burden is underscored by its association with increased ICU and hospital lengths of stay, higher healthcare costs, delayed rehabilitation, and persistent deficits affecting quality of life for months to years post-discharge. Moreover, ICU-acquired weakness (ICUAW), a broad term encompassing CIP and CIM, is recognized as an independent predictor of mortality and poor long-term outcomes.

Pathophysiology

The pathophysiology of ICU-related peripheral nerve dysfunction is multifactorial. In CIP, axonal degeneration of motor and sensory nerves is driven by systemic inflammatory responses, microvascular dysfunction, and metabolic derangements. Sepsis-induced endothelial activation leads to impaired perfusion and nerve ischemia. In CIM, there is primary muscle fiber injury with loss of thick filaments, altered membrane excitability, and energy failure. Both entities share overlapping triggers, including inflammatory cytokines, oxidative stress, and mitochondrial dysfunction. Prolonged immobility, hyperglycemia, and exposure to neurotoxic medications further exacerbate neuromuscular injury.

Risk Factors

Major risk factors include prolonged mechanical ventilation, sepsis, multi-organ dysfunction, hyperglycemia, corticosteroid use, neuromuscular blocking agents, older age, and pre-existing comorbidities such as diabetes mellitus. The cumulative burden of critical illness severity, immobilization, and systemic inflammation amplifies risk. Recent evidence also suggests that nutritional deficits, electrolyte imbalances, and episodes of hypoxemia contribute to the development of neuromuscular complications.

Clinical Features

ICU-related peripheral nerve dysfunction characteristically presents as generalized, symmetric limb weakness, often with distal predominance. Sensory deficits (such as decreased pinprick or vibration sense) are more pronounced in CIP, while CIM may present with preserved sensation but profound muscle weakness. Facial and ocular muscles are typically spared. Deep tendon reflexes are reduced or absent. Respiratory muscle involvement impairs weaning from mechanical ventilation. Clinically, differentiation between CIP, CIM, and mixed forms can be challenging at the bedside and requires systematic evaluation.

Diagnosis

Diagnosis is based on a combination of clinical assessment and electrophysiological studies. Bedside screening should include the Medical Research Council (MRC) sum score for muscle strength, where a score less than 48 is highly suggestive of ICUAW. Nerve conduction studies (NCS) and electromyography (EMG) can distinguish between axonal neuropathy (CIP) and myopathic processes (CIM). Early screening is recommended in patients with unexplained weakness, difficulty weaning, or prolonged ICU courses. Biomarkers such as creatine kinase (CK) may aid diagnosis but lack specificity. Emerging tools, including point-of-care ultrasound for muscle thickness and novel serum markers, are under investigation.

Treatment & Management

Management is largely supportive and preventive, focusing on early mobilization, optimal glycemic control, minimizing exposure to neuromuscular blockers and corticosteroids, and addressing sepsis promptly. Physical and occupational therapy should be initiated early and continued throughout recovery. Multidisciplinary approaches involving physiatrists, neurologists, and rehabilitation specialists improve outcomes. Pharmacologic therapies are limited; however, strict avoidance of iatrogenic risk factors is paramount. Nutritional optimization and maintaining electrolyte balance are also recommended.

Recent Advances / Emerging Therapies

Recent advances include the use of neuromuscular ultrasound for early detection and monitoring of muscle atrophy, and the investigation of novel biomarkers such as neurofilament light chain protein for peripheral nerve injury. Research into immunomodulatory therapies and antioxidant strategies is ongoing. Early, protocolized mobilization and the implementation of ICU bundles (ABCDEF) have shown promise in reducing incidence and severity of ICUAW. Tele-rehabilitation and wearable technologies are emerging as valuable tools for post-discharge recovery monitoring.

Guideline Recommendations

International guidelines, including those from the European Society of Intensive Care Medicine and the American Thoracic Society, recommend routine screening for neuromuscular weakness in ICU patients at risk, particularly those with sepsis or prolonged ventilation. The use of standardized bedside assessments (such as the MRC sum score), coupled with electrophysiological testing when indicated, is endorsed. Early mobilization, optimal glycemic control, and minimization of neurotoxic drug exposure remain key preventive strategies. Multidisciplinary rehabilitation is strongly advocated throughout the ICU stay and post-discharge period.

Conclusion

ICU-related peripheral nerve dysfunction is a prevalent and impactful complication among critically ill patients, with significant implications for morbidity, mortality, and quality of life. Early recognition through systematic screening, mechanism-based preventive measures, and multidisciplinary approaches are essential for optimizing outcomes. Ongoing research into pathophysiological mechanisms, novel diagnostics, and therapeutic interventions holds promise for further improving the care and recovery of this vulnerable population.